Article
Factor V Leiden mutation and high FVIII are associated with an increased risk of VTE in women with breast cancer during adjuvant tamoxifen - results from a prospective, single center, case control study.
European journal of internal medicine - 1 Jan 2015
Kovac Mirjana, Kovac Zeljko, Tomasevic Zorica, Vucicevic Slavko, Djordjevic Valentina, Pruner Iva, Radojkovic Dragica
Abstract excerpt
BACKGROUND: Estimates of the risk ratio of tamoxifen-associated venous thromboembolism (VTE) in breast cancer patients range from 2.4 to 7.1. The occurrence of thrombosis in patients with breast cancer complicates the clinical condition and causes a change of treatment. Our study was conducted in order to investigate the influence of patient-related risk factors for thrombosis development in breast cancer...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.